Table 3. Univariate Cox regression analysis of the association between SF3B1 mutation and common prognostic factors.
| All patients | Luminal B patients | PR-Negative patients | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Age | 3.351 (2.093, 5.364) | 0.000 | 6.414 (1.442, 28.528) | 0.015 | 5.584 (2.187, 14.262) | 0.000 |
| N-Index | 0.986 (0.581, 1.673) | 0.958 | 1.455 (0.510, 4.154) | 0.483 | 0.984 (0.385, 2.515) | 0.972 |
| ER status | 7.920 (2.490, 25.192) | 0.000 | / | / | 7.679 (2.271, 25.965) | 0.001 |
| PR | 1.750 (1.069, 2.865) | 0.026 | / | / | / | / |
| HER2 | 0.458 (0.198, 1.063) | 0.069 | / | / | 0.522 (0.153, 1.776) | 0.298 |
| Menopausal state | 2.430 (1.159, 5.092) | 0.019 | 1.880 (0.243, 14.522) | 0.545 | 3.118 (0.725, 13.421) | 0.127 |
| PAM50 and claudin-low | 0.807 (0.662, 0.982) | 0.033 | / | / | 0.818 (0.615, 1.088) | 0.168 |
| Neoplasm Histologic Grade | 0.859 (0.584, 1.263) | 0.440 | 0.852 (0.333, 2.179) | 0.738 | 0.507 (0.258, 0.994) | 0.048 |
| Breast cancer type | 1.200 (1.017, 1.417) | 0.031 | 1.643 (0.797, 3.384) | 0.178 | 1.398 (0.709, 2.754) | 0.333 |
| Tumor stage | 0.840 (0.575, 1.227) | 0.367 | 0.985 (0.413, 2.350) | 0.974 | 0.701 (0.335, 1.463) | 0.344 |
| Primary Tumor Laterality | 1.030 (0.641, 1.655) | 0.902 | 1.409 (0.466, 4.263) | 0.543 | 1.006 (0.406, 2.493) | 0.990 |
N-index, Nottingham prognostic index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval.